Innopac  ushered in a crucial moment – by successfully signing a Strategic Memorandum of Understanding (MOU) with EVA Pharma, a leading pharmaceutical company in Egypt!
This signing marks a solid step forward in the cooperation between the two parties and lays an important foundation for deepening their partnership in the future. The strong alliance between the two sides promises a bright future!
  About EVA Pharma
  As a benchmark enterprise in Egypt's pharmaceutical industry, EVA Pharma relies on more than a century of pharmaceutical accumulation to firmly rank among the top manufacturers of branded generic drugs in the Middle East and North Africa. Its business scope covers diverse fields such as branded generic drugs, over-the-counter (OTC) drugs and food supplements. In 2024, EVA Pharma successfully launched Egypt's first locally-developed long-acting diabetes insulin, achieving a breakthrough in the localized production of key pharmaceuticals. Adhering to strict quality standards, the company has obtained authoritative certifications from Europe, the United States and the Gulf region. Its products are sold in more than 40 countries around the world, occupying an important position in the international pharmaceutical market.